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Abstract
Background: The routine determination of drug resistance in newly HIV-1 infected individuals
documents a potential increase in the transmission of drug-resistant variants. Plasma samples from
twenty seven therapy naive HIV-1 infected Italian patients were analyzed by the line probe assay
(LIPA) and the TruGene HIV-1 assay for the detection of mutations conferring resistance to HIV-1.
Results: Both tests disclosed amino-acid substitutions associated with resistance in a variable
number of patients. In particular, two mutations (K70R and V118I), detectable by LIPA and by
sequencing analysis respectively, revealed resistance to NRTIs in two plasma samples. At least
three mutations conferring resistance to NNRTIs, not detectable by commercial LIPA, able to
reveal mutations associated only with nucleoside reverse transcriptase analogues, were disclosed
by viral sequence analysis. Moreover, most samples showed mutations correlated with resistance
to protease inhibitors. Remarkably, a key mutation, like V82A (found as a mixture), and some
"indeterminate" results (9 samples), due the absence of signal on the lines corresponding to a
specific probe, was revealed only by LIPA, while a variable number of secondary mutations was
detectable only by TruGene HIV-1 assay.
Conclusion: Even if further studies are necessary to establish the impact of different tests on the
evaluation of drug-resistant strains transmission, LIPA might be useful in a wide population analysis,
where bulk results are needed in a short time, while sequencing analysis, able to detect mutations
conferring resistance to both NRTIs and NNRTIs, might be considered a more complete assay,
albeit more expensive and more technically complex.
Background
The widespread use of antiretroviral drugs to treat hu-
man immunodeficiency virus (HIV-1) infection might re-
sult in an increasing transmission of drug-resistant
virus, compromising therapeutic options in newly infect-
ed individuals. Since some evidence indicates that viral
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resistance and treatment failure are closely linked [1,2],
routine determination of drug resistance in drug naive
HIV-1 infected individuals might be important to dis-
close single viral mutations able to influence the initial
approach to therapy [3–7]
Several cross-sectional surveys to detect primary infec-
tion involving drug resistant virus have shown a variable
prevalence (ranging from 0 to 10%) of primary muta-
tions [8,9] conferring resistance to zidovudine, lamivu-
dine or nevirapine resistant virus and protease inhibitors
[10–14].
Epidemiological surveys to clarify the prevalence of re-
sistance to HIV-1 isolates from newly infected patients is
recommended in the design of initial antiretroviral regi-
mens [11] even if plasma HIV RNA level, CD4 cell count
and clinical status, [15–17] also offer important informa-
tion for therapy initiation.
Several manufacturers have developed genotypic drug
resistance assays able to identify the individual combina-
tions of nucleotide substitutions, known to confer resist-
ance to specific antiretroviral agents, and thereby help
recognize drugs less likely to be effective. Different meth-
odologies are now available for testing HIV susceptibility
to antiretroviral drugs and are able to detect drug-resist-
ance associated with the viral enzyme reverse tran-
scriptase (RT) and protease.
The success of drug therapy depends on the ability to
suppress viral replication quickly to preserve the HIV
specific CD4+ cell helper response. Complete HIV-1 sup-
pression could be compromised in naive patients who al-
ready harbor virus with mutations conferring resistance
to antiretroviral drugs, diminishing clinical benefit and
fostering broader drug resistance [1,3]. However, deter-
mining the prevalence of drug resistant virus in patients
with established HIV infection before starting therapy
might have important positive implications. Several
studies concerning HIV naive subjects have been per-
formed [3–7] even if the choice of assay to disclose drug
mutations is not yet well characterized. The aim of our
study was to determine the presence of viral mutations in
a cohort of naive patients by two different sequence as-
says [the HIV RT and HIV Protease Line Probe Assay
(LIPA, Innogenetics, Alpharetta, GA) and the TruGene
HIV-1 assay (Visible Genetics, Toronto, Ontario, Cana-
da)] to study two different methods for detecting the
prevalence of drug resistant virus.
The relative advantages and disadvantages of the two as-
says were evaluated to identify the genetic constitution of
virus in designing the best treatment schedules. Optimi-
zation of therapies considering all the available informa-
tion, such as viral load, CD4+ T cell count and resistance
profile, might have a positive rebound in the choice of
therapy.
Results
Viral load analysis in naive HIV-1 patients
All the patients enrolled in the study showed a high level
of viral replication ranging from 1,500 to 540,000 HIV-
RNA copies/ml (median initial viral load: 60,000 HIV-
RNA copies/ml). However, all the samples could be am-
plified and the cDNA derived from plasma viral RNA was
sequenced to identify RT and protease mutations from
all 27 naive patients.
Aminoacid substitution associated with resistance to re-
verse transcriptase inhibitors (RTIs)
In our experimental conditions, K70R mutation (a mixed
pattern showing the presence of WT and MU), the first
mutation to appear in zidovudine treated patients, was
revealed only by LIPA. Moreover, nine viral samples
gave indeterminate results by LIPA, showing codons
lacking different amino acid positions (association of
M41L + T69K70 + L74V75: 1 case, F214T215: 1 case,
M184V: 1 case, T69K70: 2 cases and L74V75: 4 cases).
As expected, the presence of mutations associated with
resistance to non nucleoside reverse transcriptase inhib-
itors (NNRTIs), only revealed by sequencing analysis
showed VI 081 (associated with a reduced drug sensitiv-
ity to efavirenz plus nevirapine) [19], V118I (associated
with moderate phenotypic lamivudine resistance) [20]
and the presence of K103N (key mutation for all the
NNRIs) plus Y181C (with variable effects on susceptibil-
ity to efavirenz, besides resistance to nevirapine).
Aminoacid substitution associated with resistance pro-
tease inhibitors (PIs)
The overall frequency of secondary mutations [7,11] in
the protease region of pol was significantly greater than
that observed in RT. Ten patients did not show any mu-
tations conferring resistance to protease inhibitors by ei-
ther assay. LIPA showed V82A mutation (a mixed
pattern showing the presence of WT and MU) correlated
with resistance to indinavir and ritonavir, (Table 1) and
"indeterminate" results (I50/I54, and L90) were ob-
served in three and two cases respectively. On the other
hand, sequence analysis showed some codon substitu-
tions, probably occurring as a spontaneous genetic poly-
morphism, not correlated with key mutations. In
particular, the most frequent substitutions, by genotyp-
ing analysis, are present at codon 36 [M36I alone (7 cas-
es) or associated with L10V (2 cases)], at codon 63 [L63P
alone (5 cases) or associated with V77I (2 cases)] and at
codon 77 [V77I (5 cases)], while L10V was always found
in association with A71V or M36I [8,9].BMC Microbiology 2001, 1:30 http://www.biomedcentral.com/1471-2180/1/30
Table 1: Presence of codon substitutions associated with resistance to antiretroviral drugs (inhibitors of Reverse Transcriptase and Pro-
tease) by sequential analysis and by Line Probe assay in untreated HIV-1 patients.
Mutations associated with RT resistance to
NNRTIs1
Patients' N°3 Viral load4 by sequencing by Line Probe assay
2 240000 - K70K/R
4 8900 - L74/V75 (IR)
5 - L74/V75 (IR)
8 11000 - F214T215 (IR)
12 160000 - M41, T69/K70, T69/K70 (IR)
18 120000 - T69/K70 (IR)
20 120000 - L74/V75 (IR)
22 13000 - L74/V75 (IR)
24 4700 - T69/K70 (IR)
NNRTIs2
9 450000 V108I -
12 160000 - -
14 8600 V118I -
15 24000 K103N, Y181C -
Mutations associated with protease resistance (PIs)
Viral load by sequential analysis by LIPA
1 49000 V77I -
2 240000 - V82V/A
3 42000 L10I/L, A71V/A -
8 64000 L63P, V77I -
9 450000 M36I -
11 16000 M36I -
12 160000 L10V, M36I -
14 8600 L10V, M36I -
15 24000 L63P -
16 1500 M36I V82V/A
17 540000 L63P -
19 73000 V77I -
20 120000 M36I -
23 61000 M36I -
24 4700 L63P -
25 5800 L63P, V77I V82V/A
27 170000 V77I -
Legend: NRTIs1 nucleoside reverse transcriptase inhibitors NNRTIs2: nucleoside reverse transcriptase inhibitors 3Only patients who showed 
codon changes are reported; 4Viral load: N° of HIV-RNA copies/ml. 5IR: indeterminate results.BMC Microbiology 2001, 1:30 http://www.biomedcentral.com/1471-2180/1/30
In our experimental conditions we did not find mixed
populations by sequencing analysis.
Discussion
Results obtained showed that both tests disclosed the
presence of amino-acid substitutions associated with re-
sistance in a variable number of patients. Even if our
study, limited to a relatively small cohort, showed dis-
cordant results, our aim was to verify the presence of cir-
culating virus in a group of seropositive treatment naive
patients using two different tests.
First, LIPA represents "a key mutation concept" able to
monitor a maximum of 13 codon changes and must be
seen as an early warning of clinically relevant emerging
drug resistance [20,21]. Second, LIPA is more sensitive
for the detection of a mixed virus population but, the lim-
ited number of codons and the high number of indeter-
minate results represent major limitation [3,19,22–26].
On the other hand, the identification of K70R, a zidovu-
dine resistance mutation, and V82A, indinavir and riton-
avir resistance mutation, probably confirm the detection
of mutant(s) present in a low proportion [16,27,28] and
might explain the failure of sequence testing.
It is well known that LIPA might represent a valid meth-
od able to determine the presence of drug resistance mu-
tations rapidly and simultaneously in some but not all
codons. Bearing these data in mind, LIPA revealed at
least one mutation where sequencing analysis failed. On
the other hand, we do not underestimate the possibility
of sequencing analysis by TRUGENE to detect key muta-
tions (at least two – in our experimental conditions) con-
ferring resistance to NNRTIs, even if sequencing analysis
presents a greater complexity (i.e the sequence align-
ment, editing and interpretation of results require con-
stant operator care and attention).
We must also take into account that secondary muta-
tions might generate future problems in assessing drug
regimens since the plasma viral population early may be
relatively homogeneous and representative of the trans-
mitted species early in the infection [6] Since a high viral
load has frequently been detected in most naive patients,
a correct identification of secondary mutations is impor-
tant before embarking on an anti-retroviral therapy.
From this point of view, sequence analysis must be con-
sidered a more complete assay, than LIPA and might be
useful in a wide population analysis where bulk results
are needed in a short time.
Conclusion
The discrepancies observed in results between assays
need further in depth evaluation to identify potentially
clinically relevant mutations able to compromise future
treatment, in an era where the widespread use of pro-
tease and RT-inhibitors requires a more comprehensive
analysis of viral genotyping resistance
However, since the analysis of drug resistant viruses
might have serious implications in terms of recommen-
dations in clinical practice and epidemiological surveys,
the study of emerging viruses by ever newer assay tech-
nology, with protocol feasibility, data interpretation and
sources of data variation, together with the knowledge of
the limitations of each assay, the cost and the time con-
sumed to have a result, all play a role in selecting the op-
timal genotyping assay for the microbiology laboratory.
Even if the ultimate decisions regarding antiretroviral
therapy also incorporate information regarding patients'
clinical and virologic response to therapy and a thorough
ascertainment of treatment history, our data confirmed
the importance of monitoring the prevalence of muta-
tions in HIV-1 naive patients.
Materials and Methods
Patients
Twenty seven heterosexual HIV-1 seropositive patients
never treated with antiretroviral compounds, were ana-
lyzed for the presence of mutation associate with drug re-
sistance. All the patients were white, 20 men and 7
women, aged 21 to 38 years, enrolled in this study 1–12
months after seroconversion (mean time: 5.4± 3
months) documented by immunoenzymatic assay (Vidas
HIV Duo, BioMerieux, Marcy-L'Etoile, France) and Im-
munoblot (Chiron RIBA, HIV-l/HIV-2, Chiron Co., Em-
eryville, CA, USA). Moreover, peripheral blood CD-4
lymphocytes, counted by flow cytometry (FACScan, Bec-
ton & Dickinson, Mountain View, CA) using commercial-
ly available monoclonal antibody (Becton-Dickinson)
showed a mean baseline value of 532 ± 127/mm3.
An intensive medical evaluation excluded a history of
drug abuse and transmission was established to be by
sexual contact in all subjects.
HIV-RNA viremia
All the plasma samples were analyzed for HIV-1 RNA vi-
rus using the "Quantiplex HIV-RNA-3.0" assay (Chiron
Corporation, Emeryville, CA., USA), according to the
manufacturer's instructions. HIV RNA levels were ex-
pressed as copy number for ml of plasma and the lower
detection limit of the assay was 50 copies/ml. Plasma
samples were separated from the cell fraction by centrif-
ugation at 700 ×  g for 10 minutes and then frozen at -
70°C until tested for HIV-1 RNA.BMC Microbiology 2001, 1:30 http://www.biomedcentral.com/1471-2180/1/30
Nucleic Acid extraction
Viral RNA was isolated from EDTA treated plasma sam-
ples by using the QIAmp viral extraction kit (Qiagen Inc.,
Chatsworth, California USA) according to the manufac-
turer's instructions
Genotyping Assays
Briefly, the TRUGENE HIV-1 Genotyping Assay was
used in combination with the open gene automated DNA
sequencing System (Visible Genetics Inc. Toronto Cana-
da) to sequence protease and RT region of HIV-1 cDNA.
Testing involved simultaneous clip sequencing of the
protease and codons 35–244 of RT from amplified cDNA
in both the 3' and 5' directions. Sequences were aligned
and compared with a lymphoadenopathy-associated vi-
rus type 1 (HIV-B-LAV1) consensus sequence using Visi-
ble Genetics Librarian software. We focused on
mutations at positions in the pol gene known to be asso-
ciated with the most commonly used drugs against HIV-
1 [8,9].
The commercially available LIPA (Innogenetics Inc. Al-
pharetta, Georgia, USA) was used to detect the presence
of wild type, mutant RT (position 41, 69, 70, 74, 184 and
215*) and protease (position 30, 46/48, 50 54, 82/84
and 90**) codons, according to the test protocol recom-
mended by the manufacturer.
After HIV-RNA isolation, an RT-nested PCR was per-
formed with the biotinylated primers included in the
test. After denaturation, amplified RT and protease frag-
ments of viral RNA were incubated with LIPA membrane
test strips at 39°C for 30 min, onto which selected oligo-
nucleotide probes had been fixed. Following hybridiza-
tion a colorimetric reaction provided visual indication of
the presence or absence of wild type and mutated co-
dons.
A clear visible line is considered a positive reaction. A
wild type (WT) or mutant (MU) codon was established
when a clearly visible line was detectable where WT or
MU probes were fixed. The presence of wild type (WT) or
mutant (MU) strains at the same codon was considered a
viral strain containing WT and MU simultaneously. Re-
sults were considered "indeterminate" (missing codon)
for a codon when no reactivity was observed with the WT
and the MU probes, while the results of the other codons
were read independently.
The DNA sequences obtained from the HIV-infected pa-
tient samples were compared to the HIV consensus se-
quences derived from GenBank sequences of accession
number K02013 [18].
Footnote*: Positions: 41 [from Met to Leu (ATG to TTG
or CTG)], 69 [from Thr to Asp (from ACT to GAT)] 70
[(from Lys to Arg (from AAA to AGA)], 74 [from Leu to
Val (from TTA to GTA)], 184 [from Met to Val (from
ATG to GTG)], 214 [from Leu to Phe (from CTT to TTT)]
and 215 [from Thr to Tyr/Phe (from ACC to TAC/TTC)]
Footnote**: Positions: 30 [from Asp to Asn (from GAT
to AAT)], 46/48 [from Met to Ile (from ATG to ATA) and
from Gly to Val (from GGG to GTG)], 50 [from Ile to Val
(from ATC to GTC)], 54 [from Ile to Val (from ATC to
GCT)], 82/84 [from Val/Ile to Phe/Ala/Thr (from GTC/
ATC to TTC/GCC/ACC and from He to Val (from ATA to
GTA)] and 90 [from Leu to Met (from TTG to ATG)].
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